| Year |
Citation |
Score |
| 2020 |
Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, Kamradt K, Mostafa NM, Shebley M. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology. PMID 33045114 DOI: 10.1002/Jcph.1689 |
0.335 |
|
| 2020 |
Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet. Oncology. PMID 32171069 DOI: 10.1016/S1470-2045(20)30060-7 |
0.347 |
|
| 2020 |
Alhadab AA, Salem AH, Freise KJ. Semi-Mechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science. PMID 31961475 DOI: 10.1111/Cts.12739 |
0.314 |
|
| 2020 |
Kaufman JL, Baz RC, Harrison SJ, Quach H, Ho S, Vangsted AJ, Moreau P, Gibbs SD, Salem AH, Coppola S, Ross JA, Masud AA, Westrup S, Vue J, Maciag PC, et al. Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 38: 8511-8511. DOI: 10.1200/Jco.2020.38.15_Suppl.8511 |
0.337 |
|
| 2020 |
Goldsmith KC, Verschuur A, Morgenstern DA, van Eijkelenburg N, Federico SM, Fraser C, Forlenza CJ, Ziegler DS, Gerber NU, Khaw SL, Cooper TM, Flotho C, Prine BA, Salem AH, Unnebrink K, et al. The first report of pediatric patients with solid tumors treated with venetoclax. Journal of Clinical Oncology. 38: 10524-10524. DOI: 10.1200/Jco.2020.38.15_Suppl.10524 |
0.336 |
|
| 2020 |
Gopalakrishnan S, Menon R, Chyla B, Samineni D, Jacobson A, Kim SY, Mensing S, Salem AH. Abstract 3024: Relationship between venetoclax concentrations and undetectable MRD in patients with chronic lymphocytic leukemia Cancer Research. 80: 3024-3024. DOI: 10.1158/1538-7445.Am2020-3024 |
0.392 |
|
| 2019 |
Kurumaddali A, Salem AH, Agarwal SK. A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival. Journal of Cancer. 10: 5427-5433. PMID 31632487 DOI: 10.7150/Jca.33175 |
0.534 |
|
| 2019 |
Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, et al. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & Lymphoma. 1-10. PMID 31549889 DOI: 10.1080/10428194.2019.1657575 |
0.371 |
|
| 2019 |
Dave N, Gopalakrishnan S, Mensing S, Salem AH. Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. Clinical and Translational Science. 12: 625-632. PMID 31268229 DOI: 10.1111/Cts.12665 |
0.311 |
|
| 2019 |
Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W, Friedel A, Menon R, Salem AH. Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis. Hematological Oncology. PMID 31251400 DOI: 10.1002/Hon.2646 |
0.547 |
|
| 2019 |
Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, et al. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics. PMID 31209657 DOI: 10.1007/S40262-019-00788-8 |
0.36 |
|
| 2019 |
Salem AH, Dave N, Marbury T, Hu B, Miles D, Agarwal SK, Bueno OF, Menon RM. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clinical Pharmacokinetics. PMID 30949874 DOI: 10.1007/S40262-019-00746-4 |
0.504 |
|
| 2019 |
Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600. PMID 30892988 DOI: 10.1200/Jco.18.01600 |
0.544 |
|
| 2019 |
Lopez-Aguiar AG, Ethun CG, Pawlik TM, Tran T, Poultsides GA, Isom CA, Idrees K, Krasnick BA, Fields RC, Salem A, Weber SM, Martin RCG, Scoggins CR, Shen P, Mogal HD, et al. Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology. PMID 30877497 DOI: 10.1245/S10434-019-07306-X |
0.312 |
|
| 2019 |
Karol SE, Cooper TM, Bittencourt H, Gore L, O'Brien MM, Fraser C, Gambart M, Cario G, Zwaan CM, Bourquin J, Loh ML, Caron H, Prine B, Salem AH, Unnebrink K, et al. Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study Blood. 134: 2649-2649. DOI: 10.1182/Blood-2019-129805 |
0.342 |
|
| 2019 |
Karol SE, Alexander T, Budraja A, Pounds S, Canavera KE, Wang L, Wolf J, Klco JM, Salem AH, Palenski T, Lacayo NJ, Pui C, Opferman JT, Rubnitz J. Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia Blood. 134: 178-178. DOI: 10.1182/Blood-2019-127716 |
0.393 |
|
| 2019 |
Lacayo NJ, Pullarkat VA, Stock W, Jabbour E, Bajel A, Rubnitz J, Leonard J, Mullighan CG, Khaw SL, Vear SI, Opferman JT, Salem AH, Schmidt M, Tong B, Zhou L, et al. Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Blood. 134: 285-285. DOI: 10.1182/Blood-2019-126977 |
0.341 |
|
| 2019 |
Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Alzate S, Macartney T, Pesko J, Salem AH, Ross JA, Hong W, Maciag PC, Pauff JM, et al. Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 134: 926-926. DOI: 10.1182/Blood-2019-125871 |
0.367 |
|
| 2019 |
Zeidan AM, Pollyea DA, Garcia JS, Brunner A, Roncolato F, Borate U, Odenike O, Bajel AR, Watson AM, Götze K, Nolte F, Tan PT, Hong W, Dunbar M, Zhou Y, ... ... Salem AH, et al. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome Blood. 134: 565-565. DOI: 10.1182/Blood-2019-124994 |
0.304 |
|
| 2019 |
Bahlis N, Baz R, Harrison S, Quach H, Ho S, Vangsted AJ, Moreau P, Gibbs S, Salem AH, Ross JA, Pesko J, Westrup S, Vue J, Maciag PC, Bueno OF, et al. First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma Blood. 134: 925-925. DOI: 10.1182/Blood-2019-124407 |
0.32 |
|
| 2019 |
Behrouzi R, Bayman N, Harris M, Salem A, Hudson A, Chan C, Faivre-Finn C, Cobben D, Sheikh H, Coote J, Pemberton L, Woolf D. P2.17-02 Survival in Performance Status 3 Non-Small Cell Lung Cancer Patients Receiving Radical Radiotherapy Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1913 |
0.318 |
|
| 2019 |
Jabbour E, Mullighan CG, Pullarkat VA, Lacayo NJ, Bajel A, Rubnitz J, Leonard J, Khaw SL, Vear SI, Alexander T, Norris R, Salem A, Schmidt M, Tong B, Zhou Y, et al. Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Clinical Lymphoma Myeloma and Leukemia. 19: S184-S185. DOI: 10.1016/J.Clml.2019.07.022 |
0.323 |
|
| 2018 |
Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Advances in Therapy. PMID 30264382 DOI: 10.1007/S12325-018-0793-Y |
0.514 |
|
| 2018 |
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30060083 DOI: 10.1093/Annonc/Mdy256 |
0.377 |
|
| 2018 |
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, et al. Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10. PMID 29899021 DOI: 10.1126/Scitranslmed.Aaq1240 |
0.527 |
|
| 2018 |
Lopez-Aguiar AG, Ethun CG, McInnis MR, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, et al. Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology. PMID 29761515 DOI: 10.1002/Jso.25086 |
0.324 |
|
| 2018 |
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, ... ... Salem AH, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017766840. PMID 29715056 DOI: 10.1200/Jco.2017.76.6840 |
0.407 |
|
| 2018 |
Mangal N, Salem AH, Menon RM, Freise KJ. Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. Hematological Oncology. PMID 29672885 DOI: 10.1002/Hon.2514 |
0.342 |
|
| 2018 |
Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, et al. Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery. PMID 29404753 DOI: 10.1007/S00268-018-4530-0 |
0.33 |
|
| 2018 |
Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. European Journal of Clinical Pharmacology. PMID 29302721 DOI: 10.1007/S00228-017-2403-3 |
0.355 |
|
| 2018 |
Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Friedel A, Menon R, Salem AH. Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Blood. 132: 5239-5239. DOI: 10.1182/Blood-2018-99-116790 |
0.368 |
|
| 2017 |
Krasnick BA, Jin LX, Davidson JT, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, et al. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. Journal of Surgical Oncology. PMID 29284072 DOI: 10.1002/Jso.24836 |
0.332 |
|
| 2017 |
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. The Lancet. Oncology. PMID 29246803 DOI: 10.1016/S1470-2045(17)30909-9 |
0.332 |
|
| 2017 |
Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Weiss M, Scoggins C, Martin RCG, et al. Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology. PMID 29205351 DOI: 10.1002/Jso.24945 |
0.33 |
|
| 2017 |
Schimizzi GV, Jin LX, Davidson JT, Krasnick BA, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Weber SM, Salem A, Hawkins WG, Strasberg SM, Doyle MB, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. PMID 29169904 DOI: 10.1016/J.Hpb.2017.10.003 |
0.307 |
|
| 2017 |
Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Annals of Surgery. PMID 29064885 DOI: 10.1097/Sla.0000000000002574 |
0.305 |
|
| 2017 |
Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. PMID 29058801 DOI: 10.1002/Cpdd.395 |
0.525 |
|
| 2017 |
Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-6. PMID 29027832 DOI: 10.1080/00498254.2017.1381779 |
0.332 |
|
| 2017 |
O'Connor SC, Mogal H, Russell G, Ethun C, Fields RC, Jin L, Hatzaras I, Vitiello G, Idrees K, Isom CA, Martin R, Scoggins C, Pawlik TM, Schmidt C, Poultsides G, ... ... Salem A, et al. The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 28986752 DOI: 10.1007/S11605-017-3537-4 |
0.31 |
|
| 2017 |
Buettner S, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Weiss M, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, et al. Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 28913712 DOI: 10.1007/S11605-017-3571-2 |
0.304 |
|
| 2017 |
Li M, Dave N, Salem AH, Freise KJ. Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients. Medicine. 96: e7988. PMID 28858138 DOI: 10.1097/Md.0000000000007988 |
0.358 |
|
| 2017 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM. Blood. PMID 28847998 DOI: 10.1182/Blood-2017-06-788323 |
0.402 |
|
| 2017 |
Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma. 1-9. PMID 28797193 DOI: 10.1080/10428194.2017.1361024 |
0.344 |
|
| 2017 |
Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. Journal of Cancer. 8: 1562-1567. PMID 28775775 DOI: 10.7150/Jca.18686 |
0.519 |
|
| 2017 |
Mangal N, Salem AH, Li M, Menon R, Freise KJ. Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. Hematological Oncology. PMID 28707346 DOI: 10.1002/Hon.2463 |
0.348 |
|
| 2017 |
Xia BT, Ahmad SA, Al Humaidi AH, Hanseman DJ, Ethun CG, Maithel SK, Kooby DA, Salem A, Cho CS, Weber SM, Stocker SJ, Talamonti MS, Bentrem DJ, Abbott DE. Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Annals of Surgical Oncology. PMID 28600732 DOI: 10.1245/S10434-017-5918-Z |
0.308 |
|
| 2017 |
Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anti-Cancer Drugs. PMID 28562380 DOI: 10.1097/Cad.0000000000000522 |
0.557 |
|
| 2017 |
Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, Beal EW, Hawkins WG, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, et al. Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable? Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 28497252 DOI: 10.1007/s11605-017-3440-z |
0.315 |
|
| 2017 |
Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH. Moving beyond maximum tolerated dose for targeted oncology drugs: Use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clinical Pharmacology and Therapeutics. PMID 28419431 DOI: 10.1002/Cpt.712 |
0.38 |
|
| 2017 |
Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clinical Therapeutics. PMID 28161120 DOI: 10.1016/J.Clinthera.2017.01.003 |
0.523 |
|
| 2017 |
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016704320. PMID 28095146 DOI: 10.1200/Jco.2016.70.4320 |
0.402 |
|
| 2017 |
Freise KJ, Shebley M, Salem AH. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Journal of Clinical Pharmacology. PMID 28052338 DOI: 10.1002/Jcph.858 |
0.325 |
|
| 2017 |
Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, ... Salem A, et al. Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability. Annals of Surgery. 265: 197-204. PMID 28009746 DOI: 10.1097/Sla.0000000000001527 |
0.303 |
|
| 2017 |
Tran T, Ethun CG, Pawlik TM, Buettner S, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal H, Schmidt CR, et al. Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium. Journal of Clinical Oncology. 35: 356-356. DOI: 10.1200/Jco.2017.35.4_Suppl.356 |
0.316 |
|
| 2017 |
Tran T, Ethun CG, Pawlik TM, Buettner S, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal H, Schmidt CR, et al. Actual 5-year survivors following resection of hilar cholangiocarcinoma. Journal of Clinical Oncology. 35: 352-352. DOI: 10.1200/Jco.2017.35.4_Suppl.352 |
0.334 |
|
| 2017 |
Lopez-Aguiar AG, Ethun C, Pawlik TM, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal H, et al. Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Journal of Clinical Oncology. 35: 236-236. DOI: 10.1200/Jco.2017.35.4_Suppl.236 |
0.352 |
|
| 2017 |
Roberts AW, Xu T, Jia J, Agarwal S, Salem AH, Bellin RJ, Lam LT, Leverson JD. Do Statins Enhance the Anti-Cancer Activity of Venetoclax? Blood. 130: 1737-1737. DOI: 10.1182/Blood.V130.Suppl_1.1737.1737 |
0.4 |
|
| 2017 |
Poorman CE, Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, ... Salem A, et al. Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon. 83: 761-768. DOI: 10.1177/000313481708300735 |
0.347 |
|
| 2017 |
Ethun CG, Le N, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, et al. Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon. 83: 679-686. DOI: 10.1177/000313481708300721 |
0.357 |
|
| 2017 |
Lopez-Aguiar AG, Ethun CG, McInnis M, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, et al. Effect of perioperative transfusion on survival and recurrence after resection of gallbladder cancer: a 10-institution study from the U.S. extrahepatic biliary malignancy consortium Hpb. 19. DOI: 10.1016/J.Hpb.2017.02.216 |
0.325 |
|
| 2017 |
Fisher A, Salem A, Campbell-Flohr S, Wang X, Ma Y, Abbott D, Winslow E, Weber S. Making progress in pancreatic cancer: improvements in survival following resection Hpb. 19. DOI: 10.1016/J.Hpb.2017.02.135 |
0.306 |
|
| 2017 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Cordero J, Ross J, Munasinghe W, Jia J, Salem AH, Leverson J, Maciag P, Verdugo M, et al. A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 17: e16. DOI: 10.1016/J.Clml.2017.03.027 |
0.312 |
|
| 2016 |
Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ. Absorption, Metabolism, and Excretion of a Novel Bcl-2 Inhibitor Venetoclax in Humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27993930 DOI: 10.1124/Dmd.116.071613 |
0.501 |
|
| 2016 |
Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematological Oncology. PMID 27982454 DOI: 10.1002/Hon.2373 |
0.392 |
|
| 2016 |
Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical Drug Investigation. PMID 27910036 DOI: 10.1007/S40261-016-0485-9 |
0.519 |
|
| 2016 |
Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Effect of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor, in Patients with Non-Hodgkin Lymphoma. British Journal of Clinical Pharmacology. PMID 27859472 DOI: 10.1111/Bcp.13175 |
0.524 |
|
| 2016 |
Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin LX, Weber SM, Salem A, Martin RC, Scoggins C, et al. A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology. PMID 27812827 DOI: 10.1245/S10434-016-5637-X |
0.306 |
|
| 2016 |
Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin LX, Weber SM, Salem A, Martin RC, Scoggins C, et al. Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium. Jama Surgery. PMID 27784058 DOI: 10.1001/Jamasurg.2016.3642 |
0.341 |
|
| 2016 |
Beal EW, Wei L, Ethun CG, Black SM, Dillhoff M, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Pawlik TM, et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. PMID 27683047 DOI: 10.1016/J.Hpb.2016.08.006 |
0.319 |
|
| 2016 |
Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Pharmacokinetics. PMID 27638334 DOI: 10.1007/S40262-016-0453-9 |
0.354 |
|
| 2016 |
Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemotherapy and Pharmacology. PMID 27586967 DOI: 10.1007/S00280-016-3144-1 |
0.352 |
|
| 2016 |
Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma. Journal of Clinical Pharmacology. PMID 27558232 DOI: 10.1002/Jcph.821 |
0.557 |
|
| 2016 |
Margonis GA, Gani F, Buettner S, Amini N, Sasaki K, Andreatos N, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. PMID 27527802 DOI: 10.1016/J.Hpb.2016.05.016 |
0.304 |
|
| 2016 |
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery. PMID 27520294 DOI: 10.1158/2159-8290.Cd-16-0313 |
0.378 |
|
| 2016 |
Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins CR, et al. Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology. PMID 27495279 DOI: 10.1245/S10434-016-5470-2 |
0.325 |
|
| 2016 |
Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins CR, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. 18: 510-517. PMID 27317955 DOI: 10.1016/J.Hpb.2016.04.001 |
0.302 |
|
| 2016 |
Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. The Aaps Journal. PMID 27233802 DOI: 10.1208/S12248-016-9927-9 |
0.55 |
|
| 2016 |
Gani F, Buettner S, Margonis GA, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, et al. Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology. PMID 27198742 DOI: 10.1002/Jso.24283 |
0.311 |
|
| 2016 |
Kim Y, Amini N, Wilson A, Margonis GA, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins C, et al. Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology. PMID 27169772 DOI: 10.1200/Jco.2016.34.4_Suppl.387 |
0.324 |
|
| 2016 |
Buettner S, Wilson A, Margonis GA, Gani F, Ethun CG, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins CR, et al. Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 27121233 DOI: 10.1007/S11605-016-3155-6 |
0.325 |
|
| 2016 |
Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Effect of Low and High Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class Bcl-2 Inhibitor. Journal of Clinical Pharmacology. PMID 27029823 DOI: 10.1002/Jcph.741 |
0.496 |
|
| 2016 |
Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a Bcl-2 Inhibitor: Results of a Single- and Multiple-dose Study. Journal of Clinical Pharmacology. PMID 26953185 DOI: 10.1002/Jcph.730 |
0.524 |
|
| 2016 |
Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. The Journal of Surgical Research. 201: 38-43. PMID 26850182 DOI: 10.1016/J.Jss.2015.10.006 |
0.338 |
|
| 2016 |
Moreau P, Chanan-Khan AAA, Roberts AW, Agarwal A, Facon T, Kumar S, Touzeau C, Diehl S, Cordero J, Ross JA, Munasinghe W, Zhu M, Salem AH, Leverson J, Maciag PC, et al. Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 34: 8011-8011. DOI: 10.1200/Jco.2016.34.15_Suppl.8011 |
0.335 |
|
| 2016 |
Moreau P, Chanan-Khan AA, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Cordero J, Ross J, Munasinghe W, Jia J, Salem AH, Leverson J, Maciag P, Verdugo M, et al. Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Blood. 128: 975-975. DOI: 10.1182/Blood.V128.22.975.975 |
0.382 |
|
| 2016 |
Mangal N, Salem AH, Menon R, Freise KJ. Relationship Between Short-Term Response Rates and Long-Term Survival in Acute Myeloid Leukemia and Relapsed or Refractory Multiple Myeloma Blood. 128: 5128-5128. DOI: 10.1182/Blood.V128.22.5128.5128 |
0.349 |
|
| 2016 |
Wei A, Strickland SA, Roboz GJ, Hou J, Fiedler W, Lin TL, Martinelli G, Walter RB, Enjeti A, Fakouhi K, Darden DE, Dunbar M, Zhu M, Agarwal S, Salem AH, et al. Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia Blood. 128: 102-102. DOI: 10.1182/Blood.V128.22.102.102 |
0.368 |
|
| 2016 |
Freise KJ, Jones AK, Eckert D, Mensing S, Wong S, Humerickhouse R, Awni W, Salem AH. Abstract 2045: Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects Cancer Research. 76: 2045-2045. DOI: 10.1158/1538-7445.Am2016-2045 |
0.365 |
|
| 2015 |
Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, ... Salem A, et al. Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology. PMID 26286195 DOI: 10.1245/S10434-015-4803-X |
0.321 |
|
| 2015 |
Bagante F, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology. PMID 26234285 DOI: 10.1002/Jso.23982 |
0.315 |
|
| 2015 |
Touzeau C, Chanan-Khan A, Roberts A, Agarwal A, Facon T, Lebovic D, Moreau P, Darden D, Morris L, Ross J, Salem A, Munasinghe W, Zhu M, Leverson J, Enschede S, et al. Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 15: e272-e273. DOI: 10.1200/Jco.2015.33.15_Suppl.8580 |
0.332 |
|
| 2015 |
De Vos S, Flowers C, Wang D, Swinnen LJ, Fowler NH, Reid EG, Cordero J, Gifford M, D'Amico D, Dunbar M, Zhu M, Salem AH, Enschede SH, Ricker JL, Chien D, et al. Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL). Journal of Clinical Oncology. 33: 8535-8535. DOI: 10.1200/Jco.2015.33.15_Suppl.8535 |
0.313 |
|
| 2015 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Darden D, Morris L, Ross J, Salem AH, Munasinghe W, Zhu M, Leverson J, Maciag P, et al. Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results Blood. 126: 3038-3038. DOI: 10.1182/Blood.V126.23.3038.3038 |
0.339 |
|
| 2014 |
Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clinical Pharmacokinetics. 53: 479-88. PMID 24452810 DOI: 10.1007/S40262-013-0130-1 |
0.341 |
|
| 2014 |
Salem AH, Koenig D, Carlson D. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients Clinical Pharmacokinetics. 53: 347-359. PMID 24307488 DOI: 10.1007/S40262-013-0121-2 |
0.345 |
|
| 2014 |
Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial Agents and Chemotherapy. 58: 136-43. PMID 24145522 DOI: 10.1128/Aac.01738-13 |
0.541 |
|
| 2014 |
Salem AH, Noreddin AM. Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. Journal of Chemotherapy (Florence, Italy). 26: 80-5. PMID 24090676 DOI: 10.1179/1973947813Y.0000000106 |
0.31 |
|
| 2014 |
Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, McKeegan E, Salem A, Zhu M, Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson JD, et al. A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) Blood. 124: 118-118. DOI: 10.1182/Blood.V124.21.118.118 |
0.334 |
|
| 2012 |
Lexcen D, Salem AH, Elkhatib WF, Haynes V, Noreddin A. Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Agents Pharmaceutica Analytica Acta. DOI: 10.5772/39374 |
0.319 |
|
| Show low-probability matches. |